EP4431083A1 — Formulation of dalbavancin
Assigned to Adalvo Ltd · Expires 2024-09-18 · 2y expired
What this patent protects
The present invention relates to a pharmaceutical formulation containing dalbavancin or a pharmaceutically acceptable salt thereof, a cyclodextrin and water. The novel fonnulations have a significantly increased stability over known dalbavancin formulations.
USPTO Abstract
The present invention relates to a pharmaceutical formulation containing dalbavancin or a pharmaceutically acceptable salt thereof, a cyclodextrin and water. The novel fonnulations have a significantly increased stability over known dalbavancin formulations.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.